In four HNSCC lines (JHU-011, -013, -022, and -029), EGFR-targeted hDT806 effectively suppressed the growth and proliferation of HNSCC cells with the IC50s ranging between 0.7–24 nM. Here, EGFR is linked to head and neck squamous cell carcinoma.